Skip to main content

Opinion: Ethical Considerations of “Three-Parent” Babies

Mitochondrial replacement therapy raises important societal and ethical concerns, but should be embraced for its utility in preventing disease.

Written byJohn D. Loike and Nancy Reame
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00

© JENNY NICHOLS, WELLCOME IMAGESIn 2015, the US Congress banned the use of gene-editing techniques, such as CRISPR, for the creation of genetically modified human embryos. President Obama also signed into law a policy that precludes modification of the human germline. An unresolved issue with Congress’s ban and President Obama’s law is whether they encompass mitochondrial replacement therapy (MRT), a procedure that allows women with mitochondrial disease to give birth to unaffected children by inserting a nucleus from one of her eggs into an enucleated egg from a woman with healthy mitochondria, followed by in vitro fertilization.

A recent National Academies of Sciences, Engineering, and Medicine report stated that MRT is ethical if conducted exclusively in male embryos and limited to women with mitochondrial diseases. And recent studies have shown that mitochondrial donation has broader clinical applications beyond treating mitochondrial diseases, specifically in relation to infertility problems typically suffered by older females. In 2015, for example, a private research enterprise made headlines when its scientists revitalized senescent eggs through MRT before fertilizing them in vitro, helping an infertile couple in Canada give birth to a healthy baby boy. These expanded indications for MRT only strengthen the rationale for its use as an approved form of germline intervention.

Mitochondrial replacement therapy will probably emerge as an effective method to enable women with mitochondrial ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • John Loike

    John Loike serves as the interim director of bioethics at New York Medical College and as a professor of biology at Touro University. He served previously as the codirector for graduate studies in the Department of Physiology Cellular Biophysics and director of Special Programs in the Center for Bioethics at Columbia University College of Physicians and Surgeons. His biomedical research focuses on how human white blood cells combat infections and cancer. Loike lectures internationally on emerging topics in bioethics, organizes international conferences, and has published more than 150 papers and abstracts in the areas of immunology, cancer, and bioethics. He earned his Ph.D. from the Albert Einstein College of Medicine of Yeshiva University.

    View Full Profile
  • The Scientist Placeholder Image
    This person does not yet have a bio.View Full Profile

Related Topics

Published In

January 2017

Driving Out Disease

Scenarios for the genetic manipulation of mosquito vectors

Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems
Optimizing NGS Library Preparation for Reliable Sequencing Data

Optimizing NGS Library Preparation for Reliable Sequencing Data

Covaris
Using TCR Repertoire Sequencing to Advance Immunology Research

Using TCR Repertoire Sequencing to Advance Immunology Research

Miltenyi
Mapping Clonal Mosaicism in Aging Tissues

Mapping Clonal Mosaicism in Aging Tissues

Mission bio

Products

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo
Conceptual image of ice and frost.

The VAULT100 PRO: Inside the most advanced Stirling Ultracold ULT freezer ever built.

Stirling Ultracold logo